Blood Glucose Monitoring Market Analysis & Forecast: 2025-2032

Blood Glucose Monitoring Market Size and Forecast – 2025 to 2032

The global blood glucose monitoring market is estimated to be valued at USD 20.81 Bn in 2025 and is expected to reach USD 41.63 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 10.4% from 2025 to 2032.

Key Takeaways

• By Type, Self-monitoring blood glucose devices hold the largest market share of 46.2% in 2025 owing to the rising prevalence of diabetes.
• By Component, Glucometer devices expected to hold largest market share of 45.9% in 2025 owing to its growing awareness of diabetes management.
• By End User, Hospitals acquired the prominent market share of 36.4% in 2025 owing to the high inpatient diabetes burden.
• By Region, North America dominates the overall market with an estimated share of 39.6% in 2025 owing to the well-developed healthcare infrastructure.

Market Overview

The growing prevalence of diabetes worldwide is driving the Blood Glucose Monitoring Market, as patients and healthcare providers increasingly prioritize self-management and advanced monitoring technologies. The market includes glucometers, continuous glucose monitors, and test strips, which serve hospitals, clinics, and home care settings. Patients and providers are demanding more user-friendly, connected, and accurate devices, supported by robust healthcare infrastructure, reimbursement policies, and preventive healthcare initiatives. Continuous innovation and integration with digital health platforms are actively boosting adoption and improving patient care.

Current Events and Its Impact on the Blood Glucose Monitoring Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Blood Glucose Monitoring Market Insights, By Type - Self-monitoring blood glucose devices contribute the highest share of the market owing to its favorable reimbursement and policy support

Self-monitoring blood glucose devices hold the largest market share of 46.2% in 2025. The increasing global incidence of diabetes and the focus on patient-driven care are driving the growth of self-monitoring blood glucose (SMBG) devices. Device innovations, such as smaller sample requirements, faster readings, and smartphone connectivity, make monitoring easier and more precise. Greater awareness of preventive healthcare and supportive reimbursement policies motivate patients to monitor regularly. Furthermore, the continual need for test strips and lancets, combined with integration into digital health platforms, actively promotes widespread adoption among individuals managing diabetes at home. For instance, in July 2025, Trividia Health, Inc. announced that Pennsylvania has designated its TRUE METRIX® Self-Monitoring Blood Glucose Systems as the preferred option across all Managed Medicaid Plans and Fee-for-Service Medicaid programs.

Blood Glucose Monitoring Market Insights, By Component - Glucometer devices contribute the highest share of the market owing to its shift to home-based & preventive healthcare

Glucometer devices expected to hold largest market share of 45.9% in 2025. The rising prevalence of diabetes and the growing need for convenient at-home blood glucose management are driving demand for glucometer devices in the Blood Glucose Monitoring Market. Technological advancements, including compact designs, faster readings, and mobile app connectivity, actively improve usability and patient engagement. Patients and healthcare providers increasingly embrace regular monitoring due to heightened awareness of proactive diabetes care, supported by healthcare infrastructure and reimbursement policies. Moreover, the ongoing need for test strips and lancets, along with integration into digital health platforms, promotes widespread adoption.

In November 2024, Beurer India Pvt Ltd introduced the GL 22 Blood Glucose Monitor, developed under the brand’s ‘Make in India’ initiative. The device delivers German precision with advanced technology while being tailored to meet the specific needs of local users.

Blood Glucose Monitoring Market Insights, By End User - Hospitals contribute the highest share of the market owing to its point‑of‑care testing (POCT) efficiency

Hospitals acquired the prominent market share of 36.4% in 2025. Hospitals actively drive the Blood Glucose Monitoring Market by managing inpatient diabetes and hyperglycemia efficiently and accurately. Clinicians increasingly rely on point-of-care testing in critical care, surgical, and emergency settings, using reliable glucometers and continuous glucose monitoring systems. By implementing hospital-wide glucose management protocols and integrating data into electronic health records, hospitals enhance patient care. The focus on preventing complications, shortening hospital stays, and improving clinical outcomes motivates adoption, while advancements in connected monitoring devices and staff training facilitate real-time, seamless glucose management.

In May 2025, Government-run Niloufer Hospital introduced Amruth Swasth Bharath, an AI-based diagnostic tool that performs non-invasive blood tests and provides results in under a minute.

Regional Insights

To learn more about this report, Download Free Sample

North America Blood Glucose Monitoring Market Trends

North America dominates the overall market with an estimated share of 39.6% in 2025. In North America, several key trends are actively shaping the blood glucose monitoring market. Healthcare providers and patients are increasingly adopting continuous glucose monitoring (CGM) devices for real-time tracking. Manufacturers are integrating these devices with wearable technology and smartphone apps, while expanded reimbursement and insurance coverage support wider use. Consumers are driving demand for over-the-counter and user-friendly glucose monitors, and companies are responding by developing eco-conscious sensors and longer-lasting devices, promoting sustainability and innovation across the market.

For instance, in July 2025, Abbott announced the launch of its latest diabetes care innovation in Canada, the FreeStyle Libre 3 Plus, which is recognized as the world’s smallest sensor-based glucose monitoring device.

Asia Pacific Blood Glucose Monitoring Market Trends

In the Asia‑Pacific region, patients and healthcare providers are increasingly adopting both self-monitoring and continuous glucose monitoring systems as diabetes prevalence rises in populous countries like India and China. Telehealth platforms are actively integrating CGMs with smartphone apps to enable remote care. Simultaneously, expanding healthcare infrastructure in emerging markets supports wider access, while manufacturers are developing more affordable, connected glucometers and test-strip models, driving adoption and improving diabetes management across the region.

OMRON Healthcare India launched two new blood glucose monitors—the easy-to-use, no-coding HGM111 and the ultra-lightweight HGM112—expanding its portfolio of accessible monitoring solutions.

United States Blood Glucose Monitoring Market Trends

In the United States, patients and healthcare providers are rapidly adopting continuous glucose monitors (CGMs), supported by expanded Medicare and insurance coverage. Users are increasingly favoring factory-calibrated sensors that remove the need for finger-stick calibration, while companies like Dexcom actively launch long-lasting wearable systems. Consumers are embracing over-the-counter and mobile-connected devices, and clinicians leverage AI-powered analytics to transform glucose trends into actionable insights, enhancing diabetes management and enabling more informed decision-making for both patients and healthcare professionals.

In November 2025, DexCom, Inc., a global leader in glucose biosensing, announced it will launch the Dexcom G7 15-Day Continuous Glucose Monitoring System in the United States for adults with diabetes. Initially, the device will be available only to users receiving their Dexcom CGM through DME providers.

China Blood Glucose Monitoring Market Trends

In China, rising diabetes rates driven by urbanization and lifestyle changes are actively shaping the blood glucose monitoring market. Domestic manufacturers are introducing affordable, wireless, and wearable CGM systems that connect directly with smartphone apps. Telemedicine platforms are integrating these real-time sensors to provide remote care. The government is supporting adoption through policies and broader insurance coverage, while younger, tech-savvy users are driving the shift from traditional glucometers to more advanced, connected monitoring solutions.

End-user Feedback and Unmet Needs in the Blood Glucose Monitoring Market

• Accuracy and Reliability Concerns: Many users report variations in readings between devices or inconsistent results over time. End-users emphasize the need for highly accurate, reliable devices that can provide precise glucose measurements consistently, especially for insulin dosing decisions. Improved calibration and error reduction remain critical unmet needs.
• Ease of Use and Comfort: Patients seek devices that are simple, intuitive, and minimally invasive. Finger-prick tests can be painful and cumbersome, while wearable CGMs may cause skin irritation. Users want smaller, ergonomic devices, easy-to-read displays, and hassle-free operation to improve daily adherence and comfort.
• Data Integration and Accessibility: Many patients and clinicians desire seamless integration of glucose data with mobile apps, cloud platforms, and electronic health records. Real-time insights, trend analysis, and actionable alerts are often limited, highlighting the need for more connected, interoperable devices that support personalized care and remote monitoring.

Blood Glucose Monitoring Market Trend

Miniaturized, Skin‑Friendly Sensor Patches

The latest generation of CGM technology features ultra-thin sensor patches that adhere to the skin discreetly and comfortably. These microelectronic patches often include embedded AI that runs low-power algorithms on-device, spotting glucose trends and deviations without constant uploads. Users benefit from more seamless monitoring with lower visibility and less intrusion, making continuous tracking feel more like wearing a regular health patch rather than a medical device.

Integration with Telehealth and Remote Care

Blood glucose monitoring is increasingly entwined with telehealth platforms, enabling remote care and real-time clinician-patient communication. CGM data now feeds directly into mobile apps and cloud systems used by healthcare providers, who can monitor trends, adjust therapies, and intervene virtually. This linkage supports better disease management while reducing the need for frequent clinic visits. It also opens doors for remote coaching, virtual consultations, and integrated chronic care programs.

Blood Glucose Monitoring Market Opportunity

Integrated Digital Health Ecosystems

There’s strong potential in pairing glucose monitoring devices with telehealth platforms, insulin delivery systems, and digital therapeutics. By creating seamless, cloud-connected ecosystems that analyze data, provide predictive alerts, and deliver personalized coaching, companies can deepen user engagement and foster long-term retention.

Market Report Scope

Blood Glucose Monitoring Market News

• In November 2025, the Pan American Health Organization (PAHO) launched an online course, Caring for People with Type 2 Diabetes Mellitus in Primary Health Care, offering a free, self-paced resource to enhance the skills and knowledge of primary health care teams.
• In November 2024, Prevounce Health launched its first remote blood glucose monitoring device, the clinically validated Pylo GL1-LTE, which connects to multiple cellular networks to ensure reliable data transmission across the United States.
• In June 2025, Thane-based startup Tracky, a healthtech brand by DrStore Healthcare Services, launched India’s first Bluetooth-enabled Continuous Glucose Monitor (CGM), positioning the product to advance diabetes care and preventive health management nationwide.

Analyst Opinion (Expert Opinion)

• BGM market is poised at a fundamental inflection point, driven by a transition from episodic finger-stick devices to continuous, fully integrated glucose ecosystems. The U.S. now boasts over 3.2 million active wearable CGM users, underscoring that CGMs are no longer niche tools — they’re becoming mainstream among both Type 1 and increasingly Type 2 patients.
• On the technology front, breakthroughs in non‑invasive sensing are not just academic dreams: plasmonic nanopillar sensors now demonstrate real-time sweat‑glucose detection in wearable form, achieving detection limits of 0.12 mM, which is a credible path toward needle‑free monitoring. Similarly, other research teams are pushing machine‑learning models using skin conductance (GSR) to flag hypoglycemia without invasive hardware. If these early-stage innovations scale, they could disrupt the entire SMBG / CGM paradigm.
• While Medicare and insurers are broadening CGM reimbursement (e.g., eliminating prior onerous rules), the recurring cost of sensors still remains a barrier for wide adoption, especially beyond insulin-dependent users.
• The competitive landscape is also consolidating. Dexcom (with ~40% of the global CGM market) is leaning into longer-wear sensors — its new G7 15-day FDA-cleared system is not just about hardware; it’s about embedding the device into user lives for longer, reducing “sensor fatigue.” Meanwhile, implantables are creeping in: Senseonics’ Eversense 365 offers a year-long sensor life, which could fundamentally lower switching costs for chronic CGM users.

Market Segmentation

• Type Insights (Revenue, USD Bn, 2020 - 2032)
• • Self-monitoring blood glucose devices
  • Continuous glucose monitoring devices
  • Flash glucose monitoring devices
• Component Insights (Revenue, USD Bn, 2020 - 2032)
  • Glucometer devices
  • Test strips
  • Lancets
  • Sensors
  • Others
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Homecare Settings
  • Ambulatory Care Settings
  • Others
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Medtronic
  • ACON Laboratories, Inc.
  • Senseonics, Inc.
  • Medisana AG
  • Bionime Corporation
  • AgaMatrix Inc.
  • ARKRAY, Inc.
  • Rossmax International Ltd.
  • Dexcom, Inc.
  • Nipro Group
  • B. Braun SE
  • Nova Biomedical 
  • LifeScan IP Holdings, LLC
  • Ascensia Diabetes Care Holdings AG
  • Nemaura
  • Terumo Corporation
  • F. Hoffmann-La Roche Ltd 

Sources

Primary Research interviews

• Endocrinologists and diabetologists from academic medical centers
• Diabetes nurses and diabetes educators
• Patients using continuous glucose monitoring (CGM) systems
• Clinical staff at diabetes clinics
• Regulatory affairs experts working on glucose‑monitoring devices

Databases

• PubMed / MEDLINE — for clinical studies and review articles (e.g., non‑invasive monitoring)
• arXiv — for preprint research on emerging sensor technologies
• ScienceDirect / Elsevier — to access peer-reviewed journal content

Magazines

• Verywell Health — for news on regulatory updates (e.g., FDA clearance of implantable CGMs)
• AP News — coverage of public-health warnings, e.g., about non‑approved non‑invasive glucose wearables

Journals

• Journal of Diabetes Science and Technology — covers diabetes-monitoring technologies.
• Diabetes Care — widely cited for clinical research and standards in glucose monitoring.
• International Journal of Diabetes and Technology — for real-world CGM studies.
• Diabetology & Metabolic Syndrome — narrative reviews on CGM alarm systems.
• Sensors — on sensor technologies for non-invasive blood glucose detection.
• Journal of Clinical Diabetes — for reviews of recent innovations in CGM.

Newspapers

• Reuters — reporting on regulatory approvals / OTC CGMs.
• The Verge — for developments in tech companies working on non‑invasive glucose monitoring.

Associations

• American Diabetes Association (ADA) — policy, access, and equity in CGM use.
• Diabetes Technology Society — standardization, technology development (through associated journals like JDST)

Public Domain sources

• Wikipedia entries (carefully used) on:
• Consensus Error Grid / Parkes Error Grid (blood glucose accuracy standard)
• Clarke Error Grid (classic accuracy standard)
• Ambulatory Glucose Profile (AGP) standard reporting format
• OpenAPS (open-source artificial pancreas project) — community‑driven innovation in glucose monitoring / insulin delivery.

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of information for last 8 years